These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 17468449

  • 1. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M.
    Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
    [Abstract] [Full Text] [Related]

  • 2. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients.
    Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, Lema J, Rajeswary J, Munschauer FE, Ambrus J, Weinstock-Guttman B.
    J Neuroimmunol; 2007 Jul; 187(1-2):159-65. PubMed ID: 17512610
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
    Lampasona V, Rio J, Franciotta D, Furlan R, Avolio C, Fazio R, Lavolpe V, Vincent A, Comi G, Trojano M, Montalban X, Martino G.
    Eur Cytokine Netw; 2003 Jul; 14(3):154-7. PubMed ID: 14656689
    [Abstract] [Full Text] [Related]

  • 5. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K.
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [Abstract] [Full Text] [Related]

  • 8. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group.
    Neurology; 2005 Jul 12; 65(1):33-9. PubMed ID: 15888603
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 12; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 16. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
    Santos R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F, Ramanathan M.
    J Neuroimmunol; 2006 Jul 12; 176(1-2):125-33. PubMed ID: 16698090
    [Abstract] [Full Text] [Related]

  • 17. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G.
    Mult Scler; 2008 Mar 12; 14(2):212-8. PubMed ID: 17986510
    [Abstract] [Full Text] [Related]

  • 18. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
    Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B.
    Pharmacogenomics J; 2012 Jun 12; 12(3):238-45. PubMed ID: 21502966
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.